Navigation Links
Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
Date:9/14/2007

uld vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A -- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The birth of biotech: San Francisco, Boston, Geneva or Chicago?
2. Wicab to present BrainPort at Boston conference
3. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
4. Boston entrepreneur to enliven Milwaukee angel group
5. UW-Madisons Beebe wins scientific award
6. Researchers say scientific reporting needs more perspective, less hype
7. Wisconsin stands at the center of scientific efforts to avert flu epidemics
8. Growth prompts new location for scientific instrument manufacturer
9. UW stem cell guru outlines scientific and political future
10. Wisconsin biotech sector featured in scientific magazine
11. Scientific Protein Laboratories Acquired by New York firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... PARK, Calif., May 27 ForteBio(R), Inc., a leadin...es the development of biotherapeutic and pharmaceu...ed two new assay modules - for high-sensitivity pr...ively - for use on the company,s Octet(R) instrume...a software upgrades and will enable, for the first...
...LL, WA and VANCOUVER, May 27 /PRNewswire-FirstCall...I ) announced today that the Company will hold a l...ade at an OncoGenex hosted reception during the 20...eting (ASCO) on Saturday, May 30, 2009. The webcas...ion, OncoGenex management and guest speakers will ...
...arch has shown that certain marginalized groups i... minorities such as African Americans and Latinos ...l disasters, suffering disproportionate impoverish...udy by UCLA researchers and colleagues has found t... fears and make more behavioral changes based on t...
Other Biology Technology:ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on Its Octet(R) Platform 2OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009 2Disabled and other vulnerable groups more susceptible to terrorism fears 2
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
Breaking Biology News(10 mins):How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 1Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 2Miami Health Insurance Outlook and Update 54523 1Miami Health Insurance Outlook and Update 54523 2Miami Health Insurance Outlook and Update 54523 3Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 1Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 2Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 3Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 4Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 5Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 6Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 7Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 8Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 9Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 10Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 11Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 12Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 13
...ss announces the latest edition of an essential ...pidly changing fields of clinical medicine. Coveri...nosis, treatment, and prevention, Clinical Virolo...ls about all the medically relevant aspects of thi...tly one of the most dynamic areas of clinical medi...
...helle, NY, March 17, 2009While the Bernard Madoff ...undation, a major benefactor for life science rese...from the scandal as a minor consequence in the lar... & Biotechnology News (GEN). They look at the Mad... global financial environment that has been rocked...
... human papilloma virus (HPV)-infections can lead t...-stage to cervical cancer. Surgical treatment of t... birth in subsequent pregnancies. As the HPV-vacci...ay therefore reduce the number of preterm births. ...of HPV-vaccination. , Cervical cancer developmen...
Other Biology News:New edition available for essential virology reference 2GEN reports on Madoff scandal's impact on the life sciences 2HPV vaccine may prevent preterm births 2
...be gel adaptors, 24 glass tubes (1.5 mm ID, 180 mm... II xi cell and PROTEAN II XL wide-format cell off...ions,* including SDS-PAGE, first- and second-dimen... gradient PAGE as well as high-resolution agarose ...
SVT3-2 Diverter Valve from Bio-Rad
PROTEAN II XL Cell, wide format from Bio-Rad
PROTEAN II xi Cell, 20 cm, without spacers and combs from Bio-Rad
Biology Products: